Fusion Pharmaceuticals Stock News

Fusion Pharmaceuticals Inc. (FUSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Upgrades According to Wells Fargo, the prior rating for Rocket Companies Inc (NYSE:RKT) was changed from Equal-Weight to Overweight. In the first quarter, Rocket Companies showed an EPS of $0.15, comp

HAMILTON, ON and BOSTON, June 6, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec

HAMILTON, ON and BOSTON, May 11, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec

HAMILTON, ON and BOSTON , April 26, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as pre

HAMILTON, ON and BOSTON, Feb. 28, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in the "Novel Oncology…

Fusion Pharmaceuticals (FUSN) announced that the compensation committee of its board granted stock option awards to purchase 12.6K shares of its stock to one employee outside Fusion''s…

HAMILTON, ON and BOSTON, Jan. 21, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as pre

Fusion Pharmaceuticals Inc (FUSN) shares closed this week 32.8% higher than it did at the end of last week. The stock is currently up 58.3% year-to-date, down 45.9% over the past 12 months, and down 61.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Shares traded as high as $6.60 and as low as $4.56 this week.Shares closed 50.4% below its 52-week high and 61.4% above its 52-week low.Trading volume this week was 73.0% higher than the 10-day average and 96.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 13.1% higher than its 5-day moving average, 30.7% higher than its 20-day moving average, and 0.5% higher than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -9796.7% The company's stock price performance over the past 12 months lags the peer average by 185.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Fusion Pharmaceuticals (FUSN) has entered into a strategic research collaboration with Pepscan Therapeutics B.V

Fusion Pharmaceuticals (FUSN) has surged around 4% in after-hours trading session, after announcing the nomination of the first targeted alpha therapy ((TAT)) candidate under

Wall Street brokerages expect that Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) will report earnings per share of ($0.48) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Fusion Pharmaceuticals earnings, with estimates ranging from ($0.51) to ($0.43). Fusion Pharmaceuticals reported earnings per share of ($0.32) in the same quarter last year, which would []

B. Riley reiterated their buy rating on shares of Fusion Pharmaceuticals (NASDAQ:FUSN) in a research report sent to investors on Thursday morning, AnalystRatings.com reports. They currently have a $17.00 target price on the stock. Other equities research analysts have also issued research reports about the stock. Zacks Investment Research raised shares of Fusion Pharmaceuticals from []

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Investment analysts at B. Riley increased their FY2021 earnings per share (EPS) estimates for Fusion Pharmaceuticals in a research note issued on Wednesday, November 10th. B. Riley analyst J. Walsh now anticipates that the company will post earnings of ($1.97) per share for the year, up from their prior forecast []